Results 71 to 80 of about 25,647 (169)

Voriconazole is a safe and effective anti-fungal prophylactic agent during induction therapy of acute myeloid leukemia

Indian Journal of Medical and Paediatric Oncology, 2016
Background: Antifungal prophylaxis (AFP) reduces the incidence of invasive fungal infections (IFIs) during induction therapy of acute myeloid leukemia (AML). Posaconazole is considered the standard of care.
Akash Shah, Prasanth Ganesan, Venkatraman Radhakrishnan, Krishnarathinam Kannan, Rejiv Rajendranath, Vandana Mahajan, Varalakshmi Vijayakumar, Trivadi Ganesan, Tenali Gnana Sagar   +8 more
doaj   +1 more source

Fungicidal Activity and In Silico Studies of Triazoles Derived From Glycerol Against Neocosmospora falciformis, A Causal Agent of Guava Tree Decline

Chemistry &Biodiversity, Volume 23, Issue 6, June 2026.
Among seventeen 1,2,3‐triazoles synthetized from glycerol (4a–4q), compound 4l completely inhibited mycelial growth and eliminated N. falciformis spores at 1,000 µg/mL, exhibiting enhanced antifungalactivity and strong binding within the FsCYP51 active site, which highlights its promise as a lead candidate for antifungal development in both biological ...
Adilson Vidal Costa, Arêssa de Oliveira Correia, Breno Benvindo dos Anjos, Mariana Belizario de Oliveira, Poliana Aparecida Rodrigues Gazolla, Vagner Tebaldi de Queiroz, Juliana Alves Resende, Róbson Ricardo Teixeira, Osmair Vital de Oliveira, Gabriel Jacomin Vargas, Waldir Cintra de Jesus Júnior, Willian Bucker Moraes, Fábio Ramos Alves   +12 more
wiley   +1 more source

Evaluation of the tacrolimus drug interaction with voriconazole vs clotrimazole in heart transplant recipients

JHLT Open
Antifungal prophylaxis postheart transplant (HT) may include voriconazole or clotrimazole, which interact with tacrolimus. There is no guidance for tacrolimus adjustment when transitioning from voriconazole to clotrimazole; therefore, this study ...
Elizabeth Posney, PharmD, Chelsea Barry, PharmD, Nathan J. Verlinden, PharmD, Tara Veasey, PharmD   +3 more
doaj   +1 more source

Immune Checkpoint Inhibitor Pneumonitis Complicated by Invasive Pulmonary Aspergillosis in COPD: Diagnostic and Therapeutic Challenges

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Checkpoint inhibitor‐associated pneumonitis complicated by invasive pulmonary aspergillosis represents a diagnostic challenge in ICI‐treated patients, particularly those with COPD receiving corticosteroid therapy. Persistent or worsening respiratory abnormalities despite immunosuppressive treatment should prompt reassessment for superimposed ...
Chukwuka Elendu, Ayi T. Debua, Emeka H. Okolo, Halimat O. Sadiq   +3 more
wiley   +1 more source

Fungal‐Bacterial Interactions in Polymicrobial Infections: Hidden Threats

MicrobiologyOpen, Volume 15, Issue 3, June 2026.
ABSTRACT Polymicrobial infections involving fungi and bacteria represent a major and increasingly recognized clinical challenge, in which interkingdom interactions significantly amplify disease severity, antimicrobial resistance, and treatment failure. Rather than passive co‐existence, fungal–bacterial communities form highly coordinated systems driven
Mohammad Javad Roustaye Gourabi, Masoud Kargar, Atefeh Kamali, Javad Yasbolaghi Sharahi   +3 more
wiley   +1 more source

Voriconazole [PDF]

Reactions Weekly, 2020
  +5 more sources

An Evaluation of Foreign Clinical Data in the Approval Reviews of Antimicrobial Medicines in Japan: Considering Ethnic and Regional Differences in Data Extrapolations in Accordance With Regulatory Circumstances

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT The approval requirements in new regions that do not require domestic clinical data and the clinical data evaluation of multi‐regional clinical trials (MRCTs) and foreign clinical trials (FCTs) in the Japanese approval review processes for antimicrobial medicines were explored.
Rumiko Shimazawa, Masayuki Ikeda
wiley   +1 more source

Risk factors for voriconazole-associated hepatotoxicity in patients with liver dysfunction: a retrospective nested case–control study

Frontiers in Pharmacology
IntroductionVoriconazole is widely used to prevent and treat invasive aspergillosis. However, its use is restricted by adverse effects, including acute liver injury (ALI).
Jing Ren, Xinfeng Cai, Wei Ge, Jinlin Guo, Shan Wang, Qinhui Wang, Linna Liu, Le Yang, Qi Yang   +8 more
doaj   +1 more source

Digital Surveillance After Allogeneic Hematopoietic Stem Cell Transplantation Guides Therapeutic Interventions to Reduce Non‐Relapse Mortality

European Journal of Haematology, Volume 116, Issue 6, Page 937-942, June 2026.
ABSTRACT Introduction Allogeneic hematopoietic stem cell transplantation (HSCT) offers curative potential for many hematological malignancies; however, outcomes may be adversely affected by infections and transplant‐associated complications, contributing to non‐relapse mortality (NRM).
Lara Bischof, Katharina Egger‐Heidrich, Martin Schneider, Gregor Friedrich, Anna Massow, Johanna Vogelsang, Franziska Schmidt, Matthias Hänel, Thomas Illmer, Lynn Leppla, Alexandra Teynor, Sabina de Geest, Gabriele Muelller, Klaus H. Metzeler, Martin Bornhäuser, Uwe Platzbecker, Jan Moritz Middeke, Vladan Vučinić   +17 more
wiley   +1 more source

Neurologic Adverse Events Associated with Voriconazole Therapy: Report of Two Pediatric Cases

Case Reports in Infectious Diseases, 2016
Although voriconazole, a triazole antifungal, is a safe drug, treatment with this agent is associated with certain adverse events such as hepatic, neurologic, and visual disturbances.
Sevliya Öcal Demir, Serkan Atici, Gülşen Akkoç, Nurhayat Yakut, Nilay Baş İkizoğlu, Ela Erdem Eralp, Ahmet Soysal, Mustafa Bakir   +7 more
doaj   +1 more source